Axiom
ANALYTICS

CERTIFICATE OF ANALYSIS · 4X ESSENTIAL PANEL + 1 ADD-ON LAYER (L8)

Axiom Analytics Laboratories
2108 N St Ste N, Sacramento, CA 95816 US

AX-2026-3626-PY87

PRO-MAN-120 · Lot T-NEX-0099
Issued Oct 3, 2026 · v1
Verify: 0AFB-9A83-18E3

SCAN TO VERIFY

PASS — ALL SPECIFICATIONS MET

5 of 5 layers complete

L1	L2	L3	L4	L8
Identity	Purity	Net Peptide Content	Sterility	Fentanyl Screen

Sample & Vial Validation



Vial A: as received & analyzed

MORE VIEWS OF VIAL A



Vial A · right

Brand	**Precise Research Only**	Product	**PRO-MAN-120**
Lot / Batch	**T-NEX-0099**	Label Claim	**NAD+ 100 mg + MOTS-C 10 mg + 5-Amino-1MQ 10 mg**
Matrix	**lyophilized powder**	Sample Count	**1**
Cap Color	**Black**	Crimp Color	**Silver / Aluminum**
Contents Color	**White**	Seal Intact	**Yes**
Condition	**sealed, intact**	Received	**Sep 24, 2026**
Sampling	**client submitted**		

Test Results

Test	Specification	Result	
Identity research screen	every declared component within ±1 Da of its own theoretical mass	`3 of 3 components confirmed`	PASS
Purity validated in house	each declared component at or above its own locked purity criterion	`99.83%`	PASS
Net Peptide Content research screen	each declared component within its own locked content criterion, at the declared ratio	`124.67 mg`	PASS
Sterility · Rapid PCR research screen	Rapid PCR screen	`Target DNA not detected`	PASS
Fentanyl Screen research screen	no fentanyl or analog at or above 1 ng/mg	`none detected`	PASS

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.

Axiom
ANALYTICS

CERTIFICATE OF ANALYSIS · 4X ESSENTIAL PANEL + 1 ADD-ON LAYER (L8)

Axiom Analytics Laboratories
2108 N St Ste N, Sacramento, CA 95816 US

AX-2026-3626-PY87

PRO-MAN-120 · Lot T-NEX-0099
Issued Oct 3, 2026 · v1
Verify: 0AFB-9A83-18E3

SCAN TO VERIFY

Layer Results

1 Identity

LC-MS (ESI+)

3 of 3 components confirmed
every declared component within ±1 Da of its own theoretical mass

PASS

Component	Its criterion	Observed	Status
NAD+	663.43 Da · acceptance ±1 Da · average	663.321 Da · mass error -0.109 Da (-164.3 ppm)	PASS
MOTS-c	2174.621 Da · acceptance ±1 Da · average	2174.511 Da · mass error -0.11 Da (-50.6 ppm)	PASS
5-Amino-1MQ	159.212 Da · acceptance ±1 Da · average	159.077 Da · mass error -0.135 Da (-847.9 ppm)	PASS

Acceptance **within ±1 Da** Vial A **3 of 3 components confirmed**

2 Purity

HILIC-CAD homogeneity (universal detection) + RP-HPLC 214 nm area% (USP <621>)

99.83%
each declared component at or above its own locked purity criterion

PASS

Component	Its criterion	Observed	Status
NAD+	Expected Purity ≥ 99.25 area % · Acceptance NLT 99.25 area % · Units area % · Source Axiom Analytics SPEC-PURITY-001, Revision 1, effective 2026-08-31	99.97%	PASS
MOTS-c	Expected Purity ≥ 99.25 area % · Acceptance NLT 99.25 area % · Units area % · Source Axiom Analytics SPEC-PURITY-001, Revision 1, effective 2026-08-31	99.55%	PASS
5-Amino-1MQ	Expected Purity ≥ 99.25 area % · Acceptance NLT 99.25 area % · Units area % · Source Axiom Analytics SPEC-PURITY-001, Revision 1, effective 2026-08-31	99.97%	PASS

Acceptance **Each component NLT 99.25 area %** Vial A **99.83% · PASS**

3 Net Peptide Content

Quantitative HPLC vs reference std

124.67 mg
each declared component within its own locked content criterion, at the declared ratio

PASS

Component	Its criterion	Observed	Status
NAD+	90–110 mg (100 mg ±10%)	103.38 mg	PASS
MOTS-c	9–11 mg (10 mg ±10%)	10.57 mg	PASS
5-Amino-1MQ	9–11 mg (10 mg ±10%)	10.72 mg	PASS

Ratio, in the table's component order: observed **9.78 : 1.00 : 1.01** against declared **10.00 : 1.00 : 1.00** · source Axiom SPEC-CONTENT-001

Target **120 mg (±10%)** Vial A **124.67 mg · PASS**



4 Sterility · Rapid PCR

Rapid Microbial DNA Screen (qPCR target panel)

Target DNA not detected
Rapid PCR screen

PASS

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.

Axiom
ANALYTICS

CERTIFICATE OF ANALYSIS · 4X ESSENTIAL PANEL + 1 ADD-ON LAYER (L8)

Axiom Analytics Laboratories
2108 N St Ste N, Sacramento, CA 95816 US

AX-2026-3626-PY87

PRO-MAN-120 · Lot T-NEX-0099
Issued Oct 3, 2026 · v1
Verify: 0AFB-9A83-18E3

SCAN TO VERIFY

8 Fentanyl Screen

LC-MS/MS targeted adulterant screen

none detected
no fentanyl or analog at or above 1 ng/mg

PASS

Result	**Not detected**	Detection limit	**1 ng/mg**
Analytes screened	**Fentanyl, Acetylfentanyl, Acrylfentanyl, Butyrylfentanyl, Carfentanil, Cyclopropylfentanyl, Furanylfentanyl, Methoxyacetylfentanyl, ortho-Fluorofentanyl, Valerylfentanyl, 4-ANPP**	Source container	**A**

Reporting Scope & Limitations

`[Sterility · Rapid PCR]` Rapid PCR screen for microbial DNA. It detects DNA from live and dead organisms and is not a USP <71> sterility test or a USP <61> count. Full USP <71> sterility testing is available as an add-on.

`[Fentanyl Screen]` Targeted LC-MS/MS adulterant screen, reported as detected or not detected against its stated detection limit. A harm-reduction research screen, not an exhaustive adulterant panel.

Digital Signatures

Analyst	**Alana Reeves**	Analyst Signature	**ed25519:a70eb20c8ba104e460769bcb...**
Technical Reviewer	**Michael Niles**	Reviewer Signature	**ed25519:0abd66cd40762ebb700a3747...**
Laboratory Director	**Daniel Brennan**	Director Signature	**ed25519:93e26f5120c8f0a4ac8f8451...**

Testing is performed within Axiom's laboratory network under Axiom's methods. Every result is reviewed and released by Axiom, which issues and is responsible for this certificate. Axiom Analytics does not hold ISO/IEC 17025 accreditation. Samples are identified to the testing laboratory by an internal lot ID only. The method status of each result is shown beside it.

Each signature is an Ed25519 signature over the SHA-384 hash of this report. Scan the QR code or verify it yourself at https://axiomanalyticslab.com/verify/AX-2026-3626-PY87.

Presentation corrected 2026-10-04; results and signatures unchanged.

CRYPTOGRAPHICALLY SEALED (ed25519 + SHA-384)

SHA-384: 78528340484cc4d74df73623bf45b8ba2a03d1d9e7e0ff567b9d191c8b37346a...
Seal: ed25519:cf68335a1634b9b21d2b7015584142a84d51b467...

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.

RESEARCH USE ONLY. All analytical testing, validation reports, and interactive Certificates of Analysis (COAs) provided by Axiom Analytics are intended strictly for Research Use Only (RUO) in in-vitro or laboratory animal model environments. Axiom Analytics does not analyze, validate, evaluate, or make any representations regarding the safety, efficacy, toxicity, or legality of any tested substance for human or animal consumption, veterinary use, clinical diagnostics, food additives, cosmetics, or household applications.

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.